PMID- 27464548
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20211203
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 96
IP  - 27
DP  - 2016 Jul 19
TI  - [A dual PI3K/mTOR inhibitor, PI-103, cooperates with TRAIL in laryngeal squamous 
      carcinoma cells in vitro].
PG  - 2187-91
LID - 10.3760/cma.j.issn.0376-2491.2016.27.017 [doi]
AB  - OBJECTIVE: To investigate the effects of a dual phosphoinosmde-3-kinase (PI3K)/ 
      mammalian target of rapamycin (mTOR) inhibitor, PI-103, cooperating with tumor 
      necrosis factor-related apoptosis-inducing ligand (TRAIL) on the laryngeal 
      squamous carcinoma Hep-2 cells. METHODS: Hep-2 cells were divided into 7 groups: 
      LY294002 group, Rapamycin group, PI-103 group, LY294002+ TRAIL group, Rapamycin+ 
      TRAIL group, PI-103+ TRAIL group and control group.The cell cycle and apoptosis 
      of Hep-2 cells were assessed by flow cytometry.For PI-103 group, PI-103+ TRAIL 
      group and control group, migration and invasion ability were measured by 
      transwell migration and invasion assay respectively.The expression of relative 
      proteins in apoptosis and PI3K/AKT/mTOR signal pathway was examined by Western 
      blotting. RESULTS: Combination of PI-103 and TRAIL could make cell cycle arrest 
      at S phase (G1: 1.80%+/-0.30%; G2: 0.00), inhibit cell proliferation, and enhance 
      apoptosis (66.78%+/-2.93%) (P<0.05). Combination of PI-103 and TRAIL could 
      statistically decrease the migration and invasion number of Hep-2 cells 
      (17.0+/-3.4, 18.4+/-5.4) than that of PI-103 group (41.2+/-3.8, 41.6+/-4.7). PI-103 could 
      inhibit PI3K/AKT/mTOR signal pathway by decreasing the protein expression of 
      p-AKT and p-4E-BP1.Comparing with the control group, the expression of cysteinyl 
      aspartate specific proteinase (Caspase) 9, 8, 3 were increased while the 
      expression of Cyclin D1, Cyclin E1, p-AKT, p-4E-BP1 were decreased in PI-103 and 
      PI-103+ TRAIL group (P<0.05). CONCLUSION: Enhanced anti-tumor effects was 
      observed by combination of PI-103 and TRAIL on laryngeal cancer cells in vitro 
      and this combined administration might be a promising strategy for clinical 
      treatment of laryngeal cancer.
FAU - Gao, C L
AU  - Gao CL
AD  - Department of Otorhinolaryngology, Eye Ear Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, China.
FAU - Li, K N
AU  - Li KN
FAU - Zhou, L
AU  - Zhou L
FAU - Tao, L
AU  - Tao L
FAU - Zhang, M
AU  - Zhang M
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (CCND1 protein, human)
RN  - 0 (CCNE1 protein, human)
RN  - 0 (Chromones)
RN  - 0 (Cyclin E)
RN  - 0 (Furans)
RN  - 0 (Morpholines)
RN  - 0 (Oncogene Proteins)
RN  - 0 (PI103)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 136601-57-5 (Cyclin D1)
RN  - 31M2U1DVID (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Chromones
MH  - Cyclin D1
MH  - Cyclin E
MH  - Furans
MH  - Head and Neck Neoplasms
MH  - Humans
MH  - Laryngeal Neoplasms
MH  - Morpholines
MH  - Oncogene Proteins
MH  - Phosphatidylinositol 3-Kinases
MH  - Pyridines
MH  - Pyrimidines
MH  - *Signal Transduction
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - TNF-Related Apoptosis-Inducing Ligand
MH  - TOR Serine-Threonine Kinases
EDAT- 2016/07/29 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2016.27.017 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2016 Jul 19;96(27):2187-91. doi: 
      10.3760/cma.j.issn.0376-2491.2016.27.017.